The management of cancer is constantly evolving through the introduction of new developments related to cancer treatment and supportive care.  This has created gaps in the ability of hematology/oncology nurses to stay up-to-date with comprehensive and clinically relevant information on current an

During 2017 the US Food and Drug Administration (FDA) approved three new AML drugs and brought back a fourth that had been withdrawn in 2010.

The goal of this activity is to improve participants’ knowledge of and competence in applying immune checkpoint inhibitors in the treatment of patients with stage III NSCLC.

The goal of this activity is to improve participants’ knowledge of and competence in applying immune checkpoint inhibitors in the treatment of patients with stage III NSCLC.

The NCCN Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer Care™ attracts more than 1,600 registrants from across the United States and the globe including oncologists (in both community and academic settings), oncology fellows, nurses, pharmacists, and other healt

The NCCN Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer Care™ attracts more than 1,600 registrants from across the United States and the globe including oncologists (in both community and academic settings), oncology fellows, nurses, pharmacists, and other healt

The NCCN Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer Care™ attracts more than 1,600 registrants from across the United States and the globe including oncologists (in both community and academic settings), oncology fellows, nurses, pharmacists, and other healt

The goal of this activity is to increase participants’ knowledge of and competence in describing the regulatory approval process for biosimilars and effectively using them to replace reference products in the daily practice of treating cancer.

The goal of this activity is to improve participants’ knowledge of and competence in applying immune checkpoint inhibitors in the treatment of patients with stage III NSCLC.

The goal of this program is to ensure that members of multidisciplinary teams, including physicians, nurses, pharmacists and other relevant healthcare professionals, have the knowledge and skills necessary to apply the standards of care to their practice and healthcare setting for patients with h